草鱼出血病病毒对其它鱼的感染性研究

用草鱼出血病病鱼分离出的草鱼出血病病毒(Grass carp hemorrhage virus,GCHV)感染其它常见鱼并用ELISA方法检查感染鱼组织提取液,结果表明:青鱼、鲢鱼、布氏鳌条对GCHV抗体呈阳性反应;鲤鱼、鳙鱼、鲫鱼、团头鲂、泥鳅则呈阴性反应。综合感染鱼发病症状及死亡特征,初步认为:青鱼对GCHV是易感的,GCHV能在鲢鱼、布氏蟹条体内增值,但毒力较低,鳙鱼、鲫鱼、团头鲂、鲤鱼、泥鳅能抗GCHV感染。     

小骨窗显微手术治疗基底节区高血压脑出血的效果分析及对血清CCCK-18、CTRP-3水平的影响

目的:探讨小骨窗显微手术治疗基底节区高血压脑出血的效果及对血清gaspase切割的细胞角蛋白18(CCCK-18)、补体C1q肿瘤坏死因子相关蛋白3(CTRP-3)水平的影响。方法:选取2016年5月至2018年5月我院收治的160例基底节区高血压脑出血患者,按照随机数表法将其分为观察组(n=82)和对照组(n=78)。对照组采用传统大骨瓣开颅术治疗,观察组采用小骨窗显微手术治疗。观察和比较两组的临床疗效,血肿清除率、术中出血量、术后意识恢复时间、住院时间,治疗前后NIHSS、ADL评分、血清CCCK-18、CTRP-3水平的变化及并发症的发生情况。结果:治疗后,观察组总有效率显著高于对照组[95.12%vs. 79.48%](P0.05);血肿清除率、术中出血量、术后意识恢复时间、住院时间均显著优于对照组[(93.62±3.58)%vs.(85.40±2.19)%,(92.47±12.56)mL vs.(189.25±26.47) mL,(2.01±0.58) d vs.(8.69±2.03) d,(13.39±2.08) d vs.(19.45±3.76) d](P0.05);NIHSS评分显著低于对照组[(9.76±1.42)分vs.(20.57±3.26)分](P0.05);ADL评分显著高于对照组[(86.42±8.64)分vs.(75.39±7.02)分](P0.05);血清CCCK-18水平显著低于对照组[(201.76±32.59) U/L vs.(237.57±39.20) U/L,(29.59±5.19) ng/mL vs.(42.97±7.94)ng/mL](P0.05);CTRP-3水平显著高于对照组[(289.59±35.19)ng/mL vs.(232.97±27.94)ng/mL](P0.05);并发症总发生率显著低于对照组[3.65%(3/82) vs. 14.10%(11/78)](P0.05)。结论:小骨窗显微手术治疗基底节区高血压脑出血的疗效显著,可更有效清除血肿,缓解血肿压迫,改善神经功能,减少继发性损伤,安全性高,可能与其降低血清CCCK-18水平及升高CTRP-3水平有关。     

甲状腺素对动脉瘤性蛛网膜下腔出血大鼠脑缺氧诱导因子-1α表达的影响及其机制*

目的:探讨甲状腺素(T4)对动脉瘤性蛛网膜下腔出血后大鼠脑缺氧诱导因子-1α(HIF-1α)表达的调节及其机制。方法:72只雄性成年SD大鼠随机分为以下4组:蛛网膜下腔出血模型组(SAH)(n=18)、蛛网膜下腔出血+甲状腺素组(SAH+T4)(n=18)、蛛网膜下腔出血+溶剂组(SAH+溶剂组)(n=18)、假手术组(n=18)。颈内动脉穿刺法建立蛛网膜下腔出血的模型,术后行颅脑CT平扫,建模后立即开始给药,按3 μg/100 g腹腔注射,每隔24 h一次,连续3 d,SAH+T4组予甲状腺素干预,SAH+溶剂组予等体积溶剂干预,均在建模后72 h处死;各组6只大鼠经多聚甲醛灌注处死后石蜡包埋切片行免疫组化染色检测HIF-1α及p-Akt蛋白、6只用TUNEL法检测凋亡,6只用干湿重法做脑水肿含量检测。结果:建模成功后SAH组及SAH+T4组、SAH+溶剂组大鼠的脑组织肿胀明显,蛛网膜下腔可见暗红色血凝块。SAH组神经行为学评分、脑含水量、凋亡率、HIF-1α蛋白、p-Akt蛋白均较假手术组明显增高(P＜0.05);SAH+T4组神经行为学评分、HIF-1α蛋白、p-Akt蛋白均较SAH组明显增高,其脑含水量、凋亡均较SAH组明显减少(P＜0.05)。结论:使用T4替代治疗可以上调动脉瘤性蛛网膜下腔出血后大鼠脑HIF-1α蛋白表达水平,可能是通过激活三磷酸肌醇激酶／蛋白激酶B(PI3K/Akt)信号通路,使凋亡率减小,最终大鼠行为学得以改善,对大鼠脑产生保护作用。     

醒脑静联合纳洛酮对急性脑出血伴意识障碍患者神经功能、炎性因子和氧化应激的影响

摘要 目的：探讨纳洛酮联合醒脑静对急性脑出血（ACH）伴意识障碍患者炎性因子、神经功能和氧化应激的影响。方法：选取2017年2月~2019年12月期间我院收治的95例ACH伴意识障碍患者,按照随机数字表法将上述患者分为对照组（n=47）和研究组（n=48）,对照组患者予以纳洛酮治疗,研究组则在对照组的基础上联合醒脑静治疗,比较两组患者疗效、神经功能、炎性因子和氧化应激指标,记录两组不良反应发生情况。结果：研究组治疗10 d后的临床总有效率为91.67%（44/48）,高于对照组的74.47%（35/47）（P<0.05）。两组治疗10 d后美国国立卫生研究院卒中量表（NIHSS）评分,白介素-6（IL-6）、C反应蛋白（CRP）以及肿瘤坏死因子-α（TNF-α）、丙二醛（MDA）水平均较治疗前下降,且研究组低于对照组（P<0.05）。两组治疗10 d后超氧歧化酶 (SOD)水平均较治疗前升高,且研究组高于对照组（P<0.05）。两组不良反应发生率对比未见统计学差异（P>0.05）。结论：醒脑静联合纳洛酮治疗ACH伴意识障碍患者,疗效显著,可有效改善患者神经功能、炎性因子和氧化应激,且安全性较好。     

入院时血清钙水平与高血压性脑出血血肿体积、神经功能及预后的关系研究

摘要 目的：探讨入院时血清钙水平与高血压性脑出血血肿体积、神经功能及预后的关系。方法：选择2018年9月-2020年4月我院收治的高血压性脑出血患者102例,根据患者入院时血清钙水平将其分为低血钙组（血清钙<2.1 mmol/L, n=34）、正常血钙组（2.1 mol/L≤血清钙≤2.7 mmol/L, n=39）和高血钙组（血清钙>2.7 mmol/L, n=29）,比较各组性别、血肿体积、入院美国国立卫生研究院卒中量表（NIHSS）评分等临床资料。所有患者随访1年,观察患者格拉斯哥预后量表（GOS）评分,根据患者预后情况将患者分为预后良好组（n=84）和预后不良组（n=18）,比较两组血清钙、血肿体积、入院NIHSS评分、GOS评分。应用受试者工作特征（ROC）曲线分析血清钙水平对患者预后的预测价值。结果：三组血肿体积、入院NIHSS评分、GOS评分、1年病死率、1年再出血率、总预后不良率比较有统计学差异（P<0.05）。预后不良组血清钙水平、GOS评分显著低于预后良好组,血肿体积、入院NIHSS评分显著高于预后良好组（P<0.05）。Pearson相关性分析显示：高血压性脑出血患者入院时血清钙水平与脑出血血肿体积、入院NIHSS评分呈负相关,与GOS评分呈正相关（P＜0.05）。ROC曲线分析显示入院时血清钙预测高血压脑出血不良预后的曲线下面积为0.129（95%CI：0.073~0.179）。结论：高血压性脑出血患者入院时血清钙水平与血肿体积、神经功能及预后存在一定关联,且入院时血清钙对高血压性脑出血不良预后具有一定预测价值。     

Formation of Free Radicals and Nitric Oxide Derivative of Hemoglobin in Rats During Shock Syndrome

Free radicals have been postulated to play an important role as mediators in the pathogenesis of shock syndrome and multiple-organ failure. We attempted to directly detect the increased formation of radicals by Electron Spin Resonance (ESR) in animal models of shock, namely the endotoxin (ETX) shock or the hemorrhagic shock of the rat. In freeze-clamped lung tissue, a small but significant increase of a free radical signal was detected after ETX application. In the blood of rats under ETX shock, a significant ESR signal with a triplet hyperfine structure was observed. The latter ESR signal evolved within several hours after the application of ETX and was localized in the red blood cells. This signal was assigned to a nitric oxide (NO) adduct of hemoglobin with the tentative structur ((a2+ NO)/23+)2. The amount of hemoglobin-NO formed, up to 0.8% of total hemoglobin, indicated that under ETX shock a considerable amount of NO was produced in the vascular system. This NO production was strongly inhibited by the arginine analog N^G-monomethyl-arginine (NMMA). The ESR signal of Hb-NO was also observed after severe hemorrhagic shock. There are three questions, namely (i) the type of vascular cells and the regulation of the process forming such a large amount of NO during ETX shock, (ii) the pathophysiological implications of the formed NO, effects which have been described as cytotoxic mediator, endothelium-derived relaxing factor (EDRF) or inhibitor of platelet aggregation, and (iii) the possible use of Hb-NO for monitoring phases of shock syndrome.     

Growth hormone and outcome in patients with intracerebral hemorrhage: a pilot study

Background: Endocrine alterations of the hypothalamic-pituitary-axis are one of the first measurable physiological changes in cerebral insults. During acute stress, human growth hormone (GH) is stimulated and has shown to have a prognostic value in various diseases. Within this pilot study, we evaluated the prognostic value of GH in patients with acute intracerebral hemorrhage (ICH).

Methods: In a prospective observational study in 40 consecutive patients with ICH, GH was measured on admission. The prognostic value of GH to predict 30-day mortality and 90-day functional outcome was assessed. Favorable functional outcome was defined as Barthel Index score >85 points and Modified Rankin Scale <3 points.

Results: GH levels were increased in patients who died within 30 days as compared to survivors (0.45 (IQR 0.20–1.51) vs. 1.51 (IQR 0.91–4.08) p?=?0.03), and in patients with an unfavorable functional outcome as compared to patients with a favorable functional outcome after 90 days 0.28 (IQR 0.16–0.61) vs. 0.78 (IQR 0.31–1.99) p?=?0.03). For mortality prediction, receiver-operating-characteristics revealed an area under the curve (AUC) on admission for GH of 0.78 (95% CI 0.60–0.96), which was in the range of the Glasgow Coma Score (GCS) (AUC 0.82 (95% CI 0.59–1.00) p?=?0.80). For functional outcome prediction, GH had an AUC of 0.71 (95% CI 0.54–0.87), which was statistically not different from the GCS (AUC 0.81 (95% CI 0.68–0.94) p?=?0.36).

Conclusions: In our small cohort of patients with acute ICH, elevated GH level were associated with increased mortality and worse outcome. If confirmed in a larger study, GH levels may be used as an additional prognostic factor in ICH patients. (ClincalTrials.gov number NCT00390962).